Abcl stock forecast.

Stock Price Forecast. According to 7 stock analysts, the average 12-month stock price forecast for ABCL stock stock is $23.29, which predicts an increase of 436.64%. The lowest target is $12 and the highest is $32. On average, analysts rate ABCL stock stock as a strong buy.Disclaimer: While every effort will be made to ensure that Bureau of Meteorology radar imagery is available on these web pages, there may be occasions when equipment or communications failure make this impossible. The Bureau's ability to restore the radar display following an outage may be limited by the priority to maintain forecasting and …What this means: InvestorsObserver gives AbCellera Biologics Inc (ABCL) an overall rank of 36, which is below average. AbCellera Biologics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 36 means that 64% of stocks appear more favorable to our system. AbCellera Biologics (NASDAQ:ABCL) First Quarter 2023 ResultsKey Financial Results. Revenue: US$12.2m (down 96% from 1Q 2022). Net loss: US$40.1m (down by 124% from US$168.6m profit in 1Q 2022).ABCL stock recorded 16/30 (53%) green days with 5.07% price volatility over the last 30 days. Based on our AbCellera Biologics stock forecast, it's now a bad time to buy ABCL stock because it's trading 6.53% above our forecast. Disclaimer: This is not investment advice. The information provided is for general information purposes only.

The above table shows the analyst ABCL forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$4.83

A $14.3 billion market cap divided by 330 million shares outstanding equals a valuation of $43.33 per share. Discounting a year 2030, $43.33 valuation, using a 10% discount rate gives us a present ...

VANCOUVER, British Columbia, November 03, 2023--AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023. Find the latest AbCellera Biologics Inc. (ABCL) stock quote, history, news and other vital information to help you with your stock trading and investing. AbCellera's Q2 2023 financials reveal declining revenues and high R&D expenses, leading to caution in investment decision. Learn why I rate ABCL stock a hold.ABCL - Cup & Handle Breakout Trade Abcellera Biologics is a biotech stock setting up in a textbook cup with handle pattern. The stock has growing institutional sponsorship as shown in the chart from MarketSmith on the chart. It also has a relative strength ranking of 97/100. Shares formed a cup with a 37% depth and have since driftAbcellera ... Nov 5, 2023 · View 8 reports from 3 analysts offering long term price targets for Aditya Birla Capital Ltd.. Aditya Birla Capital Ltd. has an average target of 205.67. The consensus estimate represents an upside of 21.05% from the last price of 169.90. Reco - This broker has downgraded this stock from it's previous report. Find the latest Bristol-Myers Squibb Company (BMY) stock quote, history, news and other vital information to help you with your stock trading and investing.

Try our new Technical Analysis Screener >. AbCellera Biologics ’s ( ABCL) Moving Averages Convergence Divergence (MACD) indicator is -0.21, suggesting AbCellera Biologics is a Sell. AbCellera Biologics ’s ( ABCL) 20-Day exponential moving average is 4.29, while AbCellera Biologics ’s ( ABCL) share price is $4.43, making it a Sell ...

ABCL stock forecast for 2023 – 2027. Last updated: October 5, 2023. ABCL. AbCellera Biologics Inc. 4.43 D 1.14% (0.05) Are you interested in AbCellera Biologics Inc. stocks prediction? If yes, then on this page you will find useful information about the dynamics of the ABCL stock price in 2022-2027. Is ABCL a good long term stock? When should ...

AbCellera Biologics ’s ( ABCL) Moving Averages Convergence Divergence (MACD) indicator is -0.21, suggesting AbCellera Biologics is a Sell. AbCellera Biologics ’s ( ABCL) 20-Day exponential moving average is 4.29, while AbCellera Biologics ’s ( ABCL) share price is $4.43, making it a Sell. AbCellera Biologics ’s ( ABCL) 50-Day ...Wall Street Stock Market & Finance report, prediction for the future: You'll find the Alphabet Inc Class A share forecasts, stock quote and buy / sell signals below. According to present data Alphabet Inc Class A's GOOGL shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).AMC Entertainment Holdings, Inc. Class A Common Stock. $5.11 +0.02 +0.39%. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation ... Previous Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K. Price to Earnings (P/E) -9.8. Nov 27, 2023 · AbCellera Biologics (ABCL) is a biotech company that discovers antibodies from natural immune responses. The company has a consensus rating of Buy and a forecasted upside of 461.1% from its current price of $4.04. See the latest news, analysis, earnings, and insider trading of ABCL stock on MarketBeat. AbCellera Biologics ’s ( ABCL) Moving Averages Convergence Divergence (MACD) indicator is -0.21, suggesting AbCellera Biologics is a Sell. AbCellera Biologics ’s ( ABCL) 20-Day exponential moving average is 4.29, while AbCellera Biologics ’s ( ABCL) share price is $4.43, making it a Sell. AbCellera Biologics ’s ( ABCL) 50-Day ... May 26, 2023 · ABCL Stock Performance: A Look at May 26, 2023. On May 26, 2023, Abcellera Biologics Inc (ABCL) saw a significant increase in its stock price, with shares trading at $28.00, up 306.39% from the previous day’s closing price. This surge in price can be attributed to the positive outlook of the 9 analysts who offer 12-month price forecasts for ABCL.

View AbCellera Biologics Inc ABCL investment & stock information. Get the latest AbCellera Biologics Inc ABCL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -1,100% and 62.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for ...Future criteria checks 4/6. Palantir Technologies is forecast to grow earnings and revenue by 34.8% and 18% per annum respectively. EPS is expected to grow by 33.7% per annum. Return on equity is forecast to be 18.4% in 3 years.NASDAQ Health Care/Life Sciences Compare to Open 4.41 Prior Close 4.34 (11/21/23) 1 Day ABCL 2.07% DJIA 0.53% S&P Mid Cap 400 0.58% Health Care/Life Sciences 0.45% Overview Per-Share Earnings,...Based on short-term price targets offered by eight analysts, the average price target for AbCellera Biologics Inc. comes to $20.75. The forecasts range from a low of $10.00 to a high of $32.00.Nov 21, 2023 · According to analyst projections, ABCL’s forecast low is $10.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -639.13% plunge from its current level, while the stock would need to soar -117.39% for it to hit the projected low. AbCellera Biologics Inc (ABCL) estimates and forecasts

Jul 12, 2023 · Find the latest AbCellera (NASDAQ: ABCL) stock information. Nov 24, 2023 · On a fall, the stock will find some support from the long-term average at approximately $4.30. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. A buy signal was issued from a pivot bottom point on Friday, October 27, 2023, and so far it has risen 13.30%.

Nov 30, 2023 · Total Valuation. ABCL has a market cap or net worth of $1.37 billion. The enterprise value is $630.32 million. Market Cap. 1.37B. Enterprise Value. 630.32M. Find the latest ABVC BioPharma, Inc. (ABVC) stock quote, history, news and other vital information to help you with your stock trading and investing.For AMERISOURCEBERGEN CORP stock forecast for 2023, 2 predictions are offered for each month of 2023 with average AMERISOURCEBERGEN CORP stock forecast of $186.62, a high forecast of $187.17, and a low forecast of $186.07. The average AMERISOURCEBERGEN CORP stock forecast 2023 represents a -0.54% decrease …The 8 analysts offering 1 year price forecasts for ABCL have a max estimate of — and a min estimate of —. Analyst rating Based on 9 analysts giving stock ratings to ABCL in the past 3 months. 805.37p. (31.55% Upside) Based on 13 Wall Street analysts offering 12 month price targets for HSBC Holdings in the last 3 months. The average price target is 805.37p with a high forecast of 1,000.00p and a low forecast of 575.00p. The average price target represents a 31.55% change from the last price of 612.20p. Highest Price Target 1,000.00p.hace 4 días ... AbCellera Biologics Inc (NASDAQ:ABCL) shares, rose in value on Thursday, November 30, with the stock price down by -0.31% to the previous ...AbCellera Biologics Inc. reported earnings of -$ 0.10 per ABCL share on Nov 2, 2023. AbCellera Biologics Inc. fell short of analysts' expectations by -28.57%. Meanwhile, the company posted an EPS of -$ 0.12 last year, which is a -193.33% lower compared to the same period last year. Report Date. Nov 2, 2023.

ABCL stock recorded 16/30 (53%) green days with 5.07% price volatility over the last 30 days. Based on our AbCellera Biologics stock forecast, it's now a bad time to buy ABCL stock because it's trading 6.53% above our forecast. Disclaimer: This is not investment advice. The information provided is for general information purposes only.

Get the latest AbCellera Biologics Inc (ABCL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Oct 13, 2023 · According to data from CNN Money, the 8 analysts offering 12-month price forecasts for ABCL had a median target of $24.50, with a high estimate of $34.00 and a low estimate of $12.00. This median estimate represents a remarkable increase of +517.13% from the stock’s last price of $3.97. Oct 13, 2023 · According to data from CNN Money, the 8 analysts offering 12-month price forecasts for ABCL had a median target of $24.50, with a high estimate of $34.00 and a low estimate of $12.00. This median estimate represents a remarkable increase of +517.13% from the stock’s last price of $3.97. 4 ago 2023 ... As of Friday, August 04, AbCellera Biologics Inc's ABCL share price has dipped by 13.34%, which has investors questioning if this is right ...Nov 5, 2023 · View 8 reports from 3 analysts offering long term price targets for Aditya Birla Capital Ltd.. Aditya Birla Capital Ltd. has an average target of 205.67. The consensus estimate represents an upside of 21.05% from the last price of 169.90. Reco - This broker has downgraded this stock from it's previous report. TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comABCL Stock Forecast - Is ABCL a buy or sell? Find out now with a free analysis on AbCellera Biologics. Should I buy or sell ABCL? ABCL Stock Analysis - [Full Report] ABCL Chart by TradingView. Antibodies Stocks Antibody Stocks Biologics Stocks Database Stocks Drug Stocks Immune Stocks Natural StocksAccording to our research, ABCL stock is a bad long-term investment. ABCL share price has been in a bear cycle for the past year. AbCellera Biologics Inc. …Given its relevancies, ABCL stock gained 13% of equity value in the trailing year. Still, ABCL surprisingly ranks among the most undervalued biotech stocks to buy. Currently, the market prices ...Symbol Lookup from Yahoo Finance. Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! Finance.AbCellera Biologics (NASDAQ:ABCL) First Quarter 2023 ResultsKey Financial Results. Revenue: US$12.2m (down 96% from 1Q 2022). Net loss: US$40.1m (down by 124% from US$168.6m profit in 1Q 2022).About Key Executives Trending Stocks TSLA Tesla, Inc. Common Stock $251.50 +1.80 +0.72% AAPL Apple Inc. Common Stock $181.09 +1.29 +0.72% RIVN …

A $14.3 billion market cap divided by 330 million shares outstanding equals a valuation of $43.33 per share. Discounting a year 2030, $43.33 valuation, using a 10% discount rate gives us a present ...805.37p. (31.55% Upside) Based on 13 Wall Street analysts offering 12 month price targets for HSBC Holdings in the last 3 months. The average price target is 805.37p with a high forecast of 1,000.00p and a low forecast of 575.00p. The average price target represents a 31.55% change from the last price of 612.20p. Highest Price Target 1,000.00p.Find the latest ABVC BioPharma, Inc. (ABVC) stock quote, history, news and other vital information to help you with your stock trading and investing.Instagram:https://instagram. banks that offer temporary debit cardswhat's the value of a gold barus forex broker comparisonfutures trading simulator app ABCL. The Nasdaq Stock Market. Indicate by check mark whether the registrant (1) ... The market price of our common stock could decline if one or more of these ...ABCELLERA BIOLOGICS share price in real-time (A2QKXS / CA00288U1066), charts and analyses, news, key data, turnovers, company data. how much are gold barsguardian individual dental More than 80 oyster farms on the NSW South Coast remain closed after severe storms and flooding hit this week. It's a flip of the coin as to whether they'll be open in … www.worthy.com reviews The average twelve-month price prediction for AbCellera Biologics is $21.88 with a high price target of $34.00 and a low price target of $12.00. Learn more on ABCL's analyst rating history. Do Wall Street analysts like AbCellera Biologics more than its competitors?Based on short-term price targets offered by eight analysts, the average price target for AbCellera Biologics Inc. comes to $20.75. The forecasts range from a low of $10.00 to a high of $32.00.